Regular visits to the doctor, keeping a strict fitness routine and dieting are perceived to be the most important elements in managing and preventing diabetes, according to a recent online survey of more than 500 AccentHealth viewers with diabetes or a family history of diabetes. As many as 94% of respondents visited their doctor regularly, and the same number of respondents exercised regularly. To see more Patient Views, click here.
Among diabetes sufferers and those with a diabetic in their household, the critical role of the physician in condition management is most visible, according to a recent online survey of more than 500 AccentHealth viewers. Eight-in-10 indicate their doctor is very or somewhat involved in their own or their household member's diabetes management; half report their doctor is their primary source for condition info — 43% more than those using the second-most common source, health-related web sites.
Making regular doctor appointments is the activity done most often by respondents (78%) to live a healthy life, at least 10 percentage points higher than diet and exercise, according to a recent online survey of more than 500 AccentHealth viewers with diabetes or a family history of diabetes. As many as 70% limit alcohol consumption, and 68% monitor their diet.
The $1.1 billion deal is expected to close in the first quarter of 2016 and will include Bayer’s Contour line of blood glucose monitors and test strips, as well as lancing devices like Microlet and Elite.
The American Pharmacists Association Foundation’s diabetes management solution, the Patient Self-Management Credential for Diabetes, was highlighted at the Healthcare Leadership Council’s wellness briefing.
DexCom received Food and Drug Administration approval for its Dexcom G4 Platinum Continuous Glucose Monitor System with Share. The Share receiver uses a wireless connection via Bluetooth Low Energy between the patient’s receiver and an app on the patient’s smartphone to relay glucose information to apps on the mobile devices of up to five designated recipients, or “followers.”
Afrezza, an inhaled insulin powder, is now available by prescription in U.S. retail pharmacies, Sanofi and MannKind Corp. announced. The drug is approved by the Food and Drug Administration to control high blood sugar in adults who have type 1 and type 2 diabetes.
In December, DSN hosted its 14th annual Diabetes Roundtable, this time expanding the discussion to include other chronic conditions and community pharmacy’s role in driving prevention and improved health outcomes for patients.
Miraculins on Tuesday announced that it will be commencing a pilot program with Lovell Drugs and Pear Healthcare Solutions that will see the placement of the first stand-alone, Scout DS diabetes screening kiosks in Lovell’s retail pharmacy locations in Ontario.